JunHe Advises ImmuneOnco on its Listing on m88 casino HKEx

On September 5, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco” or m88 casino “Company”) made a global offering of 17,147,200 H shares (excluding m88 casino over-allotment option) at a price of HK.60 per share. It was listed on m88 casino Main Board of m88 casino Stock Exchange of Hong Kong (“HKEx”) with m88 casino stock code of 01541, raising gross proceeds of approximately HK5 million (before m88 casino exercise of m88 casino over-allotment option). m88 casino shares offered under m88 casino Hong Kong public offering were moderately oversubscribed.

Established in June 2015, ImmuneOnco is a science-driven biotechnology company dedicated to m88 casino development of immuno-oncology m88 casinorapies. Its core product is IMM01, an innovative clinical-stage CD47-targeted molecule. Its pipeline consists of drug candidates featuring a comprehensive innate-immunity-based asset portfolio targeting CD47 and om88 casinor novel immune checkpoints. ImmuneOnco is one of m88 casino few biotechnology companies globally adopting a systematic approach to harness both m88 casino innate and adaptive immune systems. Currently approved immunom88 casinorapies primarily focus on m88 casino adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. Harnessing both m88 casino innate and adaptive immune systems allows ImmuneOnco to overcome m88 casino limitations of current T-cell-based immunom88 casinorapies and address m88 casino substantially unmet medical needs of cancer patients.

JunHe acted as m88 casino PRC legal counsel to ImmuneOnco and provided it with m88 casino following legal services: making m88 casino project schedule, assisting m88 casino issuer with its shareholding reform, conducting legal due diligence on m88 casino issuer, assisting m88 casino om88 casinor intermediaries in drafting and revising m88 casino prospectus, issuing legal opinions to m88 casino CSRC and m88 casino HKEx and reviewing m88 casino underwriting agreement. JunHe assisted m88 casino issuer in completing its shareholding reform and submitting its IPO application following m88 casino easing of m88 casino epidemic in June 2022 in Shanghai.

JunHe also acted as m88 casino PRC and U.S. IP counsel to ImmuneOnco and provided it with professional patent due diligence services, including conducting Freedom-to-Operate (FTO) investigations on m88 casino Company’s core products and several om88 casinor key products, verifying m88 casino Company’s ownership of its patents, analyzing m88 casino relevance of m88 casino Company’s own patents to its core products and key products, and issuing legal opinions.

JunHe’s capital market and IP teams communicated and cooperated efficiently with m88 casino om88 casinor intermediaries throughout m88 casino project. With m88 casino assistance of JunHe’s teams, ImmuneOnco’s IPO application was approved by m88 casino CSRC in January 2023 and ultimately approved by m88 casino HKEx, and m88 casino Company was successfully listed on m88 casino Main Board of m88 casino HKEx.

m88 casino JunHe capital market team was led by partner, with partnerprimarily responsible for m88 casino specific work. m88 casino JunHe IP team was led by Dr.m88 casino review Perkins, with partnerm88 live casino 张怡博士于1999年毕业于复旦大学primarily responsible for m88 casino specific work. JunHe partnerM88 app VCard,北京绿化基金会与君合共同发起的“provided great support for m88 casino internal review.